Wanwisa Promsote1, Folami Lamoke Powell1, Satyam Veean1, Menaka Thounaojam2, Shanu Markand3, Alan Saul2,4, Diana Gutsaeva2, Manuela Bartoli2,4, Sylvia B Smith2,3,4, Vadivel Ganapathy5, Pamela M Martin1,2,4. 1. 1 Department of Biochemistry and Molecular Biology, The Medical College of Georgia at Augusta University , Augusta, Georgia . 2. 2 Department of Ophthalmology, The Medical College of Georgia at Augusta University , Augusta, Georgia . 3. 3 Department of Cellular Biology and Anatomy, The Medical College of Georgia at Augusta University , Augusta, Georgia . 4. 4 The Culver Vision Discovery Institute, The Medical College of Georgia at Augusta University , Augusta, Georgia . 5. 5 Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center , Lubbock, Texas.
Abstract
AIMS: Sickle retinopathy (SR) is a major cause of blindness in sickle cell disease (SCD). The genetic mutation responsible for SCD is known, however; oxidative stress and inflammation also figure prominently in the development and progression of pathology. Development of therapies for SR is hampered by the lack of (a) animal models that accurately recapitulate human SR and (b) strategies for noninvasive yet effective retinal drug delivery. This study addressed both issues by validating the Townes humanized SCD mouse as a model of SR and demonstrating the efficacy of oral administration of the antioxidant fumaric acid ester monomethyl fumarate (MMF) in the disease. RESULTS: In vivo ophthalmic imaging, electroretinography, and postmortem histological RNA and protein analyses were used to monitor retinal health and function in normal (HbAA) and sickle (HbSS) hemoglobin-producing mice over a one-year period and in additional HbAA and HbSS mice treated with MMF (15 mg/ml) for 5 months. Functional and morphological abnormalities and molecular hallmarks of oxidative stress/inflammation were evident early in HbSS retinas and increased in number and severity with age. Treatment with MMF, a known inducer of Nrf2, induced γ-globin expression and fetal hemoglobin production, improved hematological profiles, and ameliorated SR-related pathology. Innovation and Conclusion: United States Food and Drug Administration-approved formulations in which MMF is the primary bioactive ingredient are currently available to treat multiple sclerosis; such drugs may be effective for treatment of ocular and systemic complications of SCD, and given the pleiotropic effects, other nonsickle-related diseases in which oxidative stress, inflammation, and retinal vascular pathology figure prominently. Antioxid. Redox Signal. 25, 921-935.
AIMS: Sickle retinopathy (SR) is a major cause of blindness in sickle cell disease (SCD). The genetic mutation responsible for SCD is known, however; oxidative stress and inflammation also figure prominently in the development and progression of pathology. Development of therapies for SR is hampered by the lack of (a) animal models that accurately recapitulate human SR and (b) strategies for noninvasive yet effective retinal drug delivery. This study addressed both issues by validating the Townes humanized SCDmouse as a model of SR and demonstrating the efficacy of oral administration of the antioxidant fumaric acid ester monomethyl fumarate (MMF) in the disease. RESULTS: In vivo ophthalmic imaging, electroretinography, and postmortem histological RNA and protein analyses were used to monitor retinal health and function in normal (HbAA) and sickle (HbSS) hemoglobin-producing mice over a one-year period and in additional HbAA and HbSS mice treated with MMF (15 mg/ml) for 5 months. Functional and morphological abnormalities and molecular hallmarks of oxidative stress/inflammation were evident early in HbSS retinas and increased in number and severity with age. Treatment with MMF, a known inducer of Nrf2, induced γ-globin expression and fetal hemoglobin production, improved hematological profiles, and ameliorated SR-related pathology. Innovation and Conclusion: United States Food and Drug Administration-approved formulations in which MMF is the primary bioactive ingredient are currently available to treat multiple sclerosis; such drugs may be effective for treatment of ocular and systemic complications of SCD, and given the pleiotropic effects, other nonsickle-related diseases in which oxidative stress, inflammation, and retinal vascular pathology figure prominently. Antioxid. Redox Signal. 25, 921-935.
Authors: Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter Journal: J Clin Invest Date: 2003-01 Impact factor: 14.808
Authors: Menaka C Thounaojam; Ravirajsinh N Jadeja; Shubhra Rajpurohit; Diana R Gutsaeva; Brian K Stansfield; Pamela M Martin; Manuela Bartoli Journal: J Clin Med Date: 2020-06-19 Impact factor: 4.241
Authors: Dan Jiang; Renee C Ryals; Samuel J Huang; Kyle K Weller; Hope E Titus; Bryan M Robb; Firas W Saad; Ribal A Salam; Hytham Hammad; Paul Yang; Daniel L Marks; Mark E Pennesi Journal: Invest Ophthalmol Vis Sci Date: 2019-03-01 Impact factor: 4.799
Authors: Ravirajsinh N Jadeja; Malita A Jones; Ammar A Abdelrahman; Folami L Powell; Menaka C Thounaojam; Diana Gutsaeva; Manuela Bartoli; Pamela M Martin Journal: Redox Biol Date: 2019-09-29 Impact factor: 11.799